Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1641-1650 Newer>

BusinessWeek January 10, 2005 Amy Barrett	Pfizer Has Plenty Of Pain To Kill Many investors and analysts argue that while the drug company should continue to plow money into new-drug development, the company needs to aggressively reduce other costs and return greater amounts of cash to shareholders through a higher dividend.
The Motley Fool December 30, 2004 Charly Travers	Genzyme Enters Cancer Arena The approval of a new drug is a long-term opportunity for the biotech giant.
The Motley Fool December 30, 2004 Paul Elliott	Why Daddy Loves This Stock Investing a friend's hard-earned money can be every bit as unnerving as investing your own. Let's take a look at Protein Design Labs, the leader in antibody humanization technology.
The Motley Fool December 28, 2004 W.D. Crotty	Pfizer: For Value Eyes Only While clearly not for conservative investors, this pharmaceutical deserves the attention of those looking for a value play.
The Motley Fool December 28, 2004 Rich Smith	Michael Moore vs. Big Pharma The anti-industry crusader targets pharmaceuticals. Where there's panic in an industry and fear and loathing among its investors, there's likely to be an overreaction that will bury stocks that possess inside value under a ton of bad publicity.
The Motley Fool December 28, 2004 Charly Travers	It's All in the Delivery If too much risk makes you queasy, these drug companies are for you. SkyePharma... DepoMed...
The Motley Fool December 27, 2004 W.D. Crotty	Drug Safety: Investors Beware Will AstraZeneca become the latest casualty in the drug safety debate?
PC Magazine January 18, 2005 Karen Jones	Setting Sights on Bionics Optobionics has completed a series of clinical trials involving implanting a 2-milimeter silicon chip inside the eye in patients with retinitis pigmentosa, a degenerative eye disease with no cure.
The Motley Fool December 23, 2004 Meyers & Meyers	A Company Ready for Growth? IntegraMed America looks like the classic Peter Lynch investment. But, as always, investors should do their own due diligence before committing capital.
The Motley Fool December 23, 2004 W.D. Crotty	Adolor Drug Comes Up Short The biotech company announces trial results that, once again, do not meet primary end points.
<Older 1641-1650 Newer> Return to current articles.